Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

The authors examined the role of systemic adjuvant therapy in patients with high‐risk,
resected, primary melanoma. Outcomes of interest included overall survival, disease‐free …

This first German evidence-based guideline for cutaneous melanoma was developed under
the auspices of the German Dermatological Society (DDG) and the Dermatologic …

Cutaneous melanoma is typically treated with wide local excision and, when appropriate, a
sentinel node biopsy. Many patients are cured with this approach but for patients who have …

Adequate wide excision of a primary cutaneous melanoma is associated with a 10‐year
cure rate of 85% when the tumor's depth is less than 1.5 mm (American Joint Committee on …

Background Unresectable recurrent and in-transit extremity melanoma presents a dilemma
for the treating physician. While the disease is confined to the involved limb, the survival …

High risk surgically resected melanoma is associated with a less than 50% 5-year survival.
Adjuvant therapy is an appropriate treatment modality in this setting, and is more likely to be …

This article reviews the current therapy for cutaneous melanoma. Diagnosis, staging, and
prognostic evaluation, which are crucial to proper management, are discussed. Surgical …

Metastatic malignant melanoma remains a highly lethal disease with an incidence that
continues to rise. Management of melanoma includes definitive local, regional and distant …

Background: Controversy still exists about standard management of a primary melanoma.
Over the last decades randomized phase III trials have addressed questions about the width …